TECHWIRE 30
(CIX: WRAL30)  1,116.48  up arrow+25.29  (2.32 %)  Updated: 02:12 PM EST, Dec 18 2014
(NQ: Apple)  111.93  up arrow+2.52  (2.3 %)  Updated: 02:12 PM EST, Dec 18 2014
(NY: QUINTILES)  59.17  up arrow+1.63  (2.83 %)  Updated: 02:11 PM EST, Dec 18 2014
(OP: BASF SE)  86.60  up arrow+0.11  (0.13 %)  Updated: 02:10 PM EST, Dec 18 2014
(NQ: BioCryst)  11.02  up arrow+0.11  (1.01 %)  Updated: 02:11 PM EST, Dec 18 2014
(NQ: BioDelivery)  13.25  down arrow-0.72  (-5.12 %)  Updated: 02:11 PM EST, Dec 18 2014
(NQ: CEMP)  19.62  up arrow+0.49  (2.56 %)  Updated: 02:11 PM EST, Dec 18 2014
(NQ: Cisco Systems)  27.42  up arrow+0.61  (2.28 %)  Updated: 02:12 PM EST, Dec 18 2014
(NQ: Cree)  30.84  up arrow+0.68  (2.25 %)  Updated: 02:11 PM EST, Dec 18 2014
(NQ: DARA)  0.83  up arrow+0.05  (6.68 %)  Updated: 01:58 PM EST, Dec 18 2014
(NY: EMC CORPORATION)  29.59  up arrow+1.02  (3.57 %)  Updated: 02:11 PM EST, Dec 18 2014
(NQ: Extreme Networks)  3.31  down arrow-0.08  (-2.36 %)  Updated: 02:10 PM EST, Dec 18 2014
(NQ: FB)  78.02  up arrow+1.91  (2.51 %)  Updated: 02:12 PM EST, Dec 18 2014
(NY: GLAXOSMITHKLINE)  43.23  up arrow+1.19  (2.83 %)  Updated: 02:12 PM EST, Dec 18 2014
(NQ: GOOG)  507.50  up arrow+2.61  (0.52 %)  Updated: 02:11 PM EST, Dec 18 2014
(NY: IBM)  156.11  up arrow+4.18  (2.75 %)  Updated: 02:11 PM EST, Dec 18 2014
(NY: LH)  105.39  up arrow+1.83  (1.77 %)  Updated: 02:12 PM EST, Dec 18 2014
(OP: Lenovo Group)  25.57  down arrow-0.25  (-0.98 %)  Updated: 02:06 PM EST, Dec 18 2014
(NY: MRK)  58.31  up arrow+0.68  (1.18 %)  Updated: 02:12 PM EST, Dec 18 2014
(NQ: Microsoft Corp)  47.24  up arrow+1.5  (3.28 %)  Updated: 02:12 PM EST, Dec 18 2014
(NQ: NTAP)  42.61  up arrow+1.76  (4.31 %)  Updated: 02:11 PM EST, Dec 18 2014
(NY: NOVARTIS AG)  94.26  up arrow+1.97  (2.13 %)  Updated: 02:11 PM EST, Dec 18 2014
(OP: Novozymes A/S)  43.32  up arrow+0.78  (1.83 %)  Updated: 02:06 PM EST, Dec 18 2014
(NY: PFIZER)  31.72  up arrow+0.6  (1.93 %)  Updated: 02:12 PM EST, Dec 18 2014
(NQ: Pozen)  7.95  down arrow-0.15  (-1.85 %)  Updated: 02:11 PM EST, Dec 18 2014
(NY: RED HAT)  61.61  up arrow+2.13  (3.58 %)  Updated: 02:12 PM EST, Dec 18 2014
(NQ: BBRY)  10.05  up arrow+0.07  (0.7 %)  Updated: 02:11 PM EST, Dec 18 2014
(NQ: Salix)  116.08  up arrow+1.59  (1.38 %)  Updated: 02:11 PM EST, Dec 18 2014
(NQ: SQI)  14.77  down arrow-0.37  (-2.44 %)  Updated: 02:06 PM EST, Dec 18 2014

Posts tagged “Chimerix ”

10:19 a.m. Monday

RTP drug firm launching clinical trial of possible Ebola treatment

Ebola RTP-based BioCryst Pharmaceuticals is launching a clinical trial of a potential treatment for Ebola with funding support from the U.S. government. Durham-based Chimerix and GSK also are involved in the Ebola battle.

Updated December 11

Backers pledge $390M for Ebola; side effects delay one trial

Ebola Even as backers pledged $390 million for Ebola vaccines, Swiss researchers have suspended the testing of one of the leading Ebola vaccine candidates after some volunteers reported unexpected side effects. It's not the vaccine being tested by GlaxoSmithKline.

Updated December 9

NC firms help lead Ebola fight but face multiple battles

Several North Carolina firms are at the forefront of developing new treatments for the Ebola virus, but they face challenges in testing and delivering them, executives from Chimerix, Quintiles and GlaxoSmithKline say at a conference in RTP.

GSK's Donna Altenpohl GSK's Donna Altenpohl

Updated December 9

North Carolina's role in fighting Ebola highlights conference in RTP

Ebola North Carolina's role in fighting the Ebola epidemic striking western Africa and a disease that is a global threat will be discussed Monday at a conference in Research Triangle Park.

Updated December 5

Ebola NC: Conference to focus on state's role, preparations in fighting outbreak

Ebola Government, health, private sector executives will gather at a conference focusing on the Ebola outbreak and North Carolina's involvement as well as preparations for a possible health crisis here.

Updated December 1

Premium Lock Lost amid layoff news: GSK's advance toward Ebola vaccine

The Ebola outbreak isn't generating big headlines in the U.S. these days, but forthcoming layoffs at GlaxoSmithKline are a hot topic. Unfortunately for GSK, the job cuts have overshadowed the company's progress in developing the first vaccine for the deadly Ebola.

GSK's Andrew Witty talks strategy GSK's Andrew Witty talks strategy

November 19

Bill Gates helps fund Durham drug firm's Ebola fight

Billionaire Bill Gates and his foundation are providing financial support to Durham-based Chimerix, helping it ramp up production of a potential vaccine for the deadly Ebola virus.

Bloodmobile leaves RDU for Liberia Bloodmobile leaves RDU for Liberia

November 14

Premium Lock Chimerix drug chosen for Ebola tests in Africa

Ebola An international consortium says it will test an antiviral drug from Durham-based Chimerix on patients with Ebola in Africa. The Wellcome Trust is providing the funding.

October 30

Premium Lock Durham-based Chimerix gears up Ebola tests, raising $105M

Ebola Chimerix is gearing up for the FDA- approved to launch a Phase 2 clinical trial of its possible treatment for Ebola. The company also is looking to raise $105 million.

October 21

Premium Lock GSK's Ebola vaccine could be tested in January, WHO says

Ebola Tens of thousands of doses of experimental Ebola vaccines -including one from GlaxoSmithKline - could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe, a top World Health Organization official said Tuesday.

Updated October 16

Premium Lock Durham-based Chimerix speeds up Ebola testing

Ebola Chimerix says it has FDA approval to launch a Phase 2 clinical trial of its possible treatment for Ebola. The drug has already been administered to two Ebola patients, one of whom died. The new trial will test safety, tolerability and efficacy for Brincidofovir.

Updated October 8

Premium Lock Ebola patient treated with experimental drug from Durham firm dies

Ebola Outbreak The first Ebola patient diagnosed in the United States died in a Dallas hospital Wednesday, a little more than a week after his illness exposed gaps in the nation's defenses against the disease and set off a scramble to track down anyone exposed to him.

October 8

Premium Lock Journalist stricken with Ebola also receives experimental Chimerix drug

Ebola Outbreak Durham-based Chimerix is providing its experimental antiviral drug to a journalist in Nebraska. A Dallas patient also being treated for Ebola received the treatment earlier.

October 7

Premium Lock #WTWTrends for Tuesday: Nobel Prize, Chimerix, INC and Canes trending in the Triangle

Trending in the Triangle Trending in the Triangle: Get the pulse of technology in the Triangle with the best in local technology, venture, biotech, and life science news on Tuesday, Oct. 7, 2014 as curated by @WRALTechWire.

October 7

Premium Lock Experimental Chimerix drug given to Ebola patient in Dallas

Durham-based Chimerix is providing its experimental antiviral drug to a Dallas patient being treated for Ebola, an emergency step authorized by the Food and Drug Administration. The move came Monday after the FDA authorized Chimerix to accelerate testing of its antiviral treatment.

How Chimerix anti-virals work How Chimerix anti-virals work

Updated October 6

Premium Lock FDA fast-tracks testing of Durham firm's Ebola treatment

The Food and Drug Administration is accelerating testing of a potential treatment for the Ebola virus that is being developed by Durham-based Chimerix. Currently there is no cure for the virus, which has killed more than 3,000 people in West Africa.

How Chimerix anti-virals work How Chimerix anti-virals work

Updated July 16

Premium Lock Josh Hardy, treated with experimental Chimerix drug, is going home

Chimerix, the Durham-based drug company working on experimental medicine that could save the life of a seven-year-old Josh Hardy, was granted approval by the U.S. Food and Drug Administration to administer the drug to the boy in March. On Wednesday, his mother said he is doing well and going home.

Josh Hardy Josh Hardy

May 2

Premium Lock Durham firm's good FDA news; Chimerix eyes $200M; SEAL Innovation expands; Snapchat adds chat; eBay settles antitrust case

Bulldog In today's Bulldog blog roundup of technology and life science news, get the latest about drug firm Parion Sciences, a $200 million stock offering from Chimerix, details about Raleigh-based startup SEAL Innovation's expansion, Snapchat finally adds chat, and eBay settles an antitrust case.

April 9

Premium Lock Chimerix names new CEO after Moch steps down

Chimerix Kenneth Moch has resigned as chief executive of the biopharmaceutical company to "pursue other interests," the company announced on Wednesday while also naming his replacement.

Updated March 19

Premium Lock Window of opportunity: More life science IPOs in Triangle is good for all

Life Sciences A spate of Triangle life science IPOs raised more total money than those in Boston and New York in 2013, and more followed early this year. Has this open IPO window affected biotech and life science fundraising in the Triangle? Will the window remain open? One area VC suggests we may look back on 2010-2015 as a watershed time for the regional industry.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Scroll